{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:57Z","timestamp":1792800837417,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Talent Program of Chongqing","award":["cstc2024rcih-bgzxm0162"],"award-info":[{"award-number":["cstc2024rcih-bgzxm0162"]}]},{"name":"the Talent Program of Chongqing","award":["YXGD202403"],"award-info":[{"award-number":["YXGD202403"]}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["cstc2022jxjl20039"],"award-info":[{"award-number":["cstc2022jxjl20039"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Health Commission","award":["2023ZDXM029"],"award-info":[{"award-number":["2023ZDXM029"]}]},{"name":"Chongqing Health Commission","award":["2023MSXM043"],"award-info":[{"award-number":["2023MSXM043"]}]},{"name":"Scientific and Technological Research Program of Chongqing Municipal Education Commission","award":["KJQN20230013"],"award-info":[{"award-number":["KJQN20230013"]}],"id":[{"id":"https:\/\/ror.org\/031nm5713","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Project for Enhancing Scientific Research Capabilities of Chongqing University Cancer Hospital","award":["2023nlts005"],"award-info":[{"award-number":["2023nlts005"]}],"id":[{"id":"https:\/\/ror.org\/023rhb549","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Science & Technology Innovation Fund","award":["KC2021-JX-0186-129"],"award-info":[{"award-number":["KC2021-JX-0186-129"]}]},{"name":"Shapingba District Science and Technology Bureau, Chongqing Municipality","award":["2023SQKWLH021"],"award-info":[{"award-number":["2023SQKWLH021"]}]},{"name":"Shapingba District Science and Technology Bureau, Chongqing Municipality","award":["2023SQKWLH017"],"award-info":[{"award-number":["2023SQKWLH017"]}]},{"name":"Ningxia Key Research and Development Program","award":["2023BEG02037"],"award-info":[{"award-number":["2023BEG02037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07112-y","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:54:00Z","timestamp":1767664440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Haixia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongling","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"5","key":"7112_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400. https:\/\/doi.org\/10.1038\/s41571-024-00881-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"7112_CR2","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586\u201397. https:\/\/doi.org\/10.1016\/j.cell.2016.05.082.","journal-title":"Cell"},{"issue":"7","key":"7112_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0007-6.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7112_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell stem cell. 2020;26(1):17-26.e6. https:\/\/doi.org\/10.1016\/j.stem.2019.10.010.","journal-title":"Cell stem cell."},{"issue":"4","key":"7112_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933\u201345. https:\/\/doi.org\/10.1016\/j.cell.2015.03.053.","journal-title":"Cell"},{"issue":"1","key":"7112_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22676-1","volume":"12","author":"Y Hu","year":"2021","unstructured":"Hu Y, Sui X, Song F, Li Y, Li K, Chen Z, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat Commun. 2021;12(1):2581. https:\/\/doi.org\/10.1038\/s41467-021-22676-1.","journal-title":"Nat Commun"},{"issue":"8","key":"7112_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1048.","journal-title":"JAMA Oncol"},{"issue":"2","key":"7112_CR8","doi-asserted-by":"publisher","first-page":"100911","DOI":"10.1016\/j.xcrm.2022.100911","volume":"4","author":"HM Wang","year":"2023","unstructured":"Wang HM, Zhang CY, Peng KC, Chen ZX, Su JW, Li YF, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell reports Medicine. 2023;4(2):100911. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100911.","journal-title":"Cell reports Medicine."},{"issue":"1\u20132","key":"7112_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373-86.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.11.010.","journal-title":"Cell."},{"key":"7112_CR10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60747","author":"E De Crignis","year":"2021","unstructured":"De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.60747.","journal-title":"Elife"},{"issue":"9","key":"7112_CR11","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11(9):1724\u201343. https:\/\/doi.org\/10.1038\/nprot.2016.097.","journal-title":"Nat Protoc"},{"issue":"6","key":"7112_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HHN Yan","year":"2018","unstructured":"Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, et al. A Comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell stem cell. 2018;23(6):882-97.e11. https:\/\/doi.org\/10.1016\/j.stem.2018.09.016.","journal-title":"Cell stem cell."},{"issue":"5","key":"7112_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/jnci\/djz196","volume":"112","author":"JF Dekkers","year":"2020","unstructured":"Dekkers JF, Whittle JR, Vaillant F, Chen HR, Dawson C, Liu K, et al. Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids. J Natl Cancer Inst. 2020;112(5):540\u20134. https:\/\/doi.org\/10.1093\/jnci\/djz196.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"7112_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174(6):1586-98.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.07.009.","journal-title":"Cell."},{"issue":"1","key":"7112_CR15","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41467-020-16432-0","volume":"11","author":"K Lohmussaar","year":"2020","unstructured":"Lohmussaar K, Kopper O, Korving J, Begthel H, Vreuls CPH, van Es JH, et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. Nat Commun. 2020;11(1):2660. https:\/\/doi.org\/10.1038\/s41467-020-16432-0.","journal-title":"Nat Commun"},{"issue":"11","key":"7112_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, Lohmussaar K, Kopper O, Vreuls CPH, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep. 2020;31(11):107762. https:\/\/doi.org\/10.1016\/j.celrep.2020.107762.","journal-title":"Cell Rep"},{"issue":"5","key":"7112_CR17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349. https:\/\/doi.org\/10.1038\/s41591-019-0422-6.","journal-title":"Nat Med"},{"issue":"6","key":"7112_CR18","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104013","volume":"39","author":"K Hoffmann","year":"2020","unstructured":"Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J. 2020;39(6):e104013. https:\/\/doi.org\/10.15252\/embj.2019104013.","journal-title":"EMBO J"},{"key":"7112_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.017","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018. https:\/\/doi.org\/10.1016\/j.cell.2018.03.017.","journal-title":"Cell."},{"issue":"9","key":"7112_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0349.","journal-title":"Cancer Discov"},{"issue":"10","key":"7112_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","volume":"25","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Wu C, O\u2019Rourke KP, Szeglin BC, Zheng Y, Sauve CG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25(10):1607\u201314. https:\/\/doi.org\/10.1038\/s41591-019-0584-2.","journal-title":"Nat Med."},{"issue":"5","key":"7112_CR22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-19-1376","volume":"26","author":"R Shi","year":"2020","unstructured":"Shi R, Radulovich N, Ng C, Liu N, Notsuda H, Cabanero M, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res. 2020;26(5):1162\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1376.","journal-title":"Clin Cancer Res"},{"key":"7112_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111327","author":"N Palechor-Ceron","year":"2019","unstructured":"Palechor-Ceron N, Krawczyk E, Dakic A, Simic V, Yuan H, Blancato J, et al. Conditional reprogramming for patient-derived cancer models and next-generation living biobanks. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8111327.","journal-title":"Cells"},{"issue":"1","key":"7112_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15422","volume":"8","author":"S Balani","year":"2017","unstructured":"Balani S, Nguyen LV, Eaves CJ. Modeling the process of human tumorigenesis. Nat Commun. 2017;8(1):15422. https:\/\/doi.org\/10.1038\/ncomms15422.","journal-title":"Nat Commun"},{"issue":"6","key":"7112_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338\u201350. https:\/\/doi.org\/10.1038\/nrclinonc.2012.61.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"7112_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.Cd-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinsk\u00e1 E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-0001.","journal-title":"Cancer Discov"},{"issue":"6378","key":"7112_CR27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136. https:\/\/doi.org\/10.1126\/science.aao2774.","journal-title":"Science"},{"issue":"17","key":"7112_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36898","volume":"10","author":"Q Lin","year":"2024","unstructured":"Lin Q, Ma W, Xu M, Xu Z, Wang J, Liang Z, et al. A clinical prognostic model related to T cells based on machine learning for predicting the prognosis and immune response of ovarian cancer. Heliyon. 2024;10(17):e36898. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36898.","journal-title":"Heliyon"},{"key":"7112_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2025.103851","volume":"150","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Gupta G. PARP1-PROTACs providing novel opportunities in precision oncology by targeting DNA damage response. DNA Repair (Amst). 2025;150:103851. https:\/\/doi.org\/10.1016\/j.dnarep.2025.103851.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"7112_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(2):515-28.e17. https:\/\/doi.org\/10.1016\/j.cell.2018.03.017.","journal-title":"Cell."},{"issue":"43","key":"7112_CR31","doi-asserted-by":"publisher","first-page":"13308","DOI":"10.1073\/pnas.1516689112","volume":"112","author":"F Weeber","year":"2015","unstructured":"Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A. 2015;112(43):13308\u201311. https:\/\/doi.org\/10.1073\/pnas.1516689112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"7112_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110146","volume":"37","author":"N Yucer","year":"2021","unstructured":"Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, et al. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Rep. 2021;37(13):110146. https:\/\/doi.org\/10.1016\/j.celrep.2021.110146.","journal-title":"Cell Rep"},{"issue":"3","key":"7112_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.Ccr-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764\u201375. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2287.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7112_CR34","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdw142.","journal-title":"Ann Oncol"},{"issue":"3","key":"7112_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41(3):609\u201317. https:\/\/doi.org\/10.1200\/JCO.22.01549.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7112_CR36","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3.","journal-title":"Lancet Oncol"},{"issue":"11","key":"7112_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241.","journal-title":"Ann Oncol"},{"issue":"25","key":"7112_CR38","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"issue":"11","key":"7112_CR39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr., et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0474.","journal-title":"Cancer Discov"},{"key":"7112_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106232","volume":"179","author":"M Tao","year":"2022","unstructured":"Tao M, Sun F, Wang J, Wang Y, Zhu H, Chen M, et al. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. Pharmacol Res. 2022;179:106232. https:\/\/doi.org\/10.1016\/j.phrs.2022.106232.","journal-title":"Pharmacol Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07112-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:22:21Z","timestamp":1768299741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7112"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07112-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent, and the research protocol was reviewed and approved by the Ethics Committee of Chongqing Cancer Hospital (CZLS2020274-A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}